By Fineline Cube 
On August 22, 2025, Kite Pharma, Inc., a subsidiary of Gilead Sciences (NASDAQ: GILD), announced a definitive agreement to acquire Interius BioTherapeutics for $350 million. Interius, a privately held biotech company, focuses on developing in vivo CAR therapies. This acquisition will integrate Interius’s in vivo platform with Kite’s cell therapy expertise.
Acquisition Details
Under the terms of the agreement, Kite will acquire all of Interius’s outstanding shares for a total cash consideration of $350 million, subject to customary adjustments. The payment will be made upon the closing of the transaction.
Strategic Significance
The integration of Interius’s in vivo CAR platform with Kite’s cell therapy capabilities is expected to enhance innovation in cancer treatments, leveraging advanced technologies to expand the reach and efficacy of cell-based therapies.-Fineline Info & Tech